InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $4.250 0.16 (3.91%)+
Announcement
Release
2 Jun 2026 8:30AM
Price at Release
$4.090
Full Release
download
Summary
4DMedical Limited has announced the launch of CLEAR (Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism), a clinical evidence program designed to fast-track the entry of their CT:VQ™ technology into the U.S. pulmonary embolism market, aiming to expand it to a US$3B opportunity. CT:VQ™ provides a contrast-free, functional lung assessment, more suitable than current standards like CTPA, which are overused and less efficient. Partnering with Mass General Brigham, the program involves significant investment to accelerate this market entry, potentially displacing the nuclear VQ market, and reshaping acute CT imaging workflows globally.
Key Points
  • 4DMedical launches CLEAR to fast-track CT:VQ™ entry into the pulmonary embolism market.
  • CLEAR program aims to expand the U.S. market for CT:VQ™ to US$3B.
  • CT:VQ™ offers a contrast-free functional lung assessment within standard CT workflows.
  • 4DMedical is partnering with Mass General Brigham for clinical trials.
  • CT:VQ™ is set to compete with CTPA, the current standard for PE imaging.
  • The program could potentially replace the nuclear VQ market in the U.S.
  • 4DMedical aims to reshape global acute CT imaging workflows.
  • The company's CLEAR initiative involves a US$2M investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.